Pfizer Inc. $PFE Shares Bought by Conscious Wealth Investments LLC

by · The Cerbat Gem

Conscious Wealth Investments LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 0.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 140,957 shares of the biopharmaceutical company’s stock after purchasing an additional 706 shares during the period. Pfizer makes up approximately 2.2% of Conscious Wealth Investments LLC’s holdings, making the stock its 24th biggest position. Conscious Wealth Investments LLC’s holdings in Pfizer were worth $3,425,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Brighton Jones LLC boosted its holdings in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after buying an additional 618,117 shares during the period. Revolve Wealth Partners LLC raised its stake in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 2,087 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of Pfizer by 38.7% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 1,182,830 shares of the biopharmaceutical company’s stock worth $29,027,000 after buying an additional 330,019 shares during the period. Verity Asset Management Inc. grew its holdings in Pfizer by 108.0% during the first quarter. Verity Asset Management Inc. now owns 76,276 shares of the biopharmaceutical company’s stock valued at $1,933,000 after purchasing an additional 39,608 shares during the period. Finally, Amalgamated Bank raised its holdings in shares of Pfizer by 1.5% during the first quarter. Amalgamated Bank now owns 1,101,526 shares of the biopharmaceutical company’s stock worth $27,913,000 after acquiring an additional 16,085 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Down 0.0%

PFE stock opened at $24.76 on Tuesday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company’s 50 day moving average is $24.86 and its 200 day moving average is $24.21. The stock has a market cap of $140.75 billion, a price-to-earnings ratio of 13.17, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $29.17.

Pfizer (NYSE:PFE – Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same quarter last year, the firm posted $0.60 earnings per share. The firm’s revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio is 91.49%.

Analysts Set New Price Targets

Several research firms have issued reports on PFE. Morgan Stanley dropped their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. Bank of America raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. UBS Group reiterated a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research report on Wednesday, October 1st. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Finally, Citigroup lifted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Pfizer presently has an average rating of “Hold” and an average price target of $28.13.

Get Our Latest Stock Report on PFE

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Further Reading

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).